Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 28, 2022
Seer, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of(Commission(I.R.S. Employer
incorporation)File Number)Identification No.)
3800 Bridge Parkway, Suite 102
Redwood City, California 94065
(Address of principal executive offices, including zip code)

(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last reports)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each classTrading SymbolName of each exchange on which registered
Class A Common Stock, par value $0.00001 per shareSEER
The NASDAQ Stock Market LLC
(The NASDAQ Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 – Results of Operations and Financial Condition.

On February 28, 2022, Seer, Inc. (the "Company") issued a press release (the “Press Release”) announcing results for the quarter and year ended December 31, 2021. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.

The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits

Exhibit No.Description
Press Release dated February 28, 2022
104Cover Page Interactive Data File (formatted as Inline XBRL)


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

February 28, 2022/s/ David Horn
David Horn
Chief Financial Officer

EX-99.1 2 a8k-12312021exhibit.htm EX-99.1 Document

Ex 99.1
Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook

Demonstrated tangible market progress and shipped 17 instruments through year end 2021
REDWOOD CITY, Calif. Feb 28, 2022 – Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021.

“This has been a momentous year for Seer, one that paved the way for our technology in the hands of lighthouse collaborators and customers, demonstrated the unique benefits of our technology, and positioned Seer to open up new possibilities for researchers with an unbiased, scalable approach to proteomics,” said Omid Farokhzad, Chief Executive Officer and Chair, “As we enter 2022, we are excited about our market opportunity, confident in what the Proteograph Product Suite can deliver and ready to serve an expanding customer base as we move forward with broad commercial release of the Proteograph.”

Recent Highlights
Revenue of $6.6 million for the full year 2021, inclusive of $3.1 million for the fourth quarter
Commenced broad commercial release of the Proteograph Product Suite, with multiple orders pre-booked
Created the Proteogenomics Consortium with Discovery Life Sciences and SCIEX in January 2022, a first-of-its-kind, multi-year collaboration for large-scale studies, to offer deep, unbiased proteomics with capacity ramping to over 100,000 samples per year
Launched the Centers of Excellence program with providers in North America, Europe, and Asia Pacific
Added Meeta Gulyani, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany and Rachel Haurwitz, Ph.D, CEO of Caribou Biosciences, to the Board of Directors
Fourth Quarter 2021 Financial Results
Revenue was $3.1 million for the three months ended December 31, 2021, as compared to $336 thousand for the three months ended December 31, 2020. The increase was the result of increased sales of the Proteograph Product Suite, including SP100 instruments, consumable kits and product evaluations in the fourth of quarter of 2021. Product-related revenue was $3.0 million, including $1.2 million of related party revenue, and grant revenue was $34 thousand.

Gross profit, inclusive of grant revenue, was $1.4 million and gross margin was 47% for the fourth quarter of 2021.

Operating expenses were $21.3 million for the fourth quarter of 2021, as compared to $13.4 million for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation and increased costs related to being a publicly traded company.

Net loss was $19.7 million for the fourth quarter of 2021, as compared to $12.9 million for the corresponding prior year period.

Full Year 2021 Financial Results

Revenue was $6.6 million for the year ended December 31, 2021, as compared to $656 thousand for the year ended December 31, 2020. Product-related revenue was $5.9 million, including $2.3 million of related party revenue, service revenue was $500 thousand and grant and other revenue was $223 thousand.

Gross profit, inclusive of grant revenue, was $3.4 million and gross margin was 52% for the full year 2021.

Operating expenses were $74.9 million for the full year 2021, as compared to $34.3 million for the corresponding prior year period.

Net loss was $71.2 million for the full year 2021, as compared to $32.8 million for the corresponding prior year period.

Cash, cash equivalents and investments were $493.3 million as of December 31, 2021.

2022 Guidance
Seer expects full year 2022 revenue to be in the range of $14.0 million to $16.0 million. In 2022, Seer also expects to continue to increase investments in its commercial, operations and research and development activities in order to drive long-term growth and value creation.

Webcast Information
Seer will host a conference call to discuss the fourth quarter and full year 2021 financial results on Monday, February 28, 2022 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.

About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect the Company’s current views with respect to certain current and future events and financial performance. Words such as “expects,” “anticipates,” “projects,” “intends,” “plans,” “believes,” “estimates,” variations of such words, and similar expressions are also intended to identify such forward-looking statements. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including but not limited to statements regarding the Company’s outlook for fiscal year 2022 and its ability to imagine and pioneer new ways to decode the secrets of the proteome to improve human health. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, to be filed with the SEC on March 1, 2022, and other documents the Company subsequently files with the SEC from time to time. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
Carrie Mendivil

Media Contact:
Karen Possemato


Seer, Inc.
(In thousands, except share and per share amounts)
Three Months Ended December 31,
Year Ended December 31,
Product$    1,882$    —$    3,577$    —
Related party1,1502,317
Grant and other34336223656
Total revenue3,0663366,617656
Cost of revenue:
Related party411863
Total cost of revenue1,6333,205
Gross profit1,4333363,412656
Operating expenses:
Research and development8,2155,42229,12118,942
Selling, general and administrative13,0927,95545,76415,363
Total operating expenses21,30713,37774,88534,305
Loss from operations(19,874)(13,041)(71,473)(33,649)
Other income (expense):
Interest income157105326883
Interest expense(22)(22)
Other expense(9)
Total other income135105304874
Net loss$ (19,739)$ (12,936)$ (71,169)$ (32,775)
Net loss per share attributable to common stockholders, basic and diluted    
$ (0.32)$    (0.54) $ (1.17)$    (2.48)
Weighted-average common shares outstanding, basic and diluted    


Seer, Inc.
(in thousands, except share and per share amounts)
December 31,
Current assets:
Cash and cash equivalents$    232,813$ 333,585
Short-term investments167,26198,278
Accounts receivable, net2,495
Related party receivables1,28399
Other receivables366163
Prepaid expenses and other current assets3,336452
Total current assets411,699433,128
Long-term investments93,186
Operating lease right-of-use assets20,142
Property and equipment, net13,0878,441
Restricted cash524343
Other assets501407
Total assets$    539,139$    442,319
Current liabilities:
Accounts payable$    3,789$    2,115
Accrued expenses7,3715,147
Accrued research and development1,023396
Deferred revenue376250
Deferred rent, current186
Operating lease liabilities, current864
Total current liabilities13,4238,094
Deferred rent, net of current portion1,899
Operating lease liabilities, net of current portion22,459
Other noncurrent liabilities341717
Total liabilities36,22310,710
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2021 and 2020; zero shares issued and outstanding as of December 31, 2021 and 2020    
Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2021 and 2020; 57,493,005 and 53,395,319 shares issued and outstanding as of December 31, 2021 and 2020, respectively;     
Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2021 and 2020; 4,522,478 and 5,865,732 shares issued and outstanding as of December 31, 2021 and 2020, respectively;     
Additional paid-in capital629,981486,915
Accumulated other comprehensive income (loss)(536)54
Accumulated deficit(126,530)(55,361)
Total stockholders’ equity502,916431,609
Total liabilities and stockholders’ equity$    539,139$ 442,319

EX-101.SCH 3 seer-20220228.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 seer-20220228_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Fiscal Period Focus Document Fiscal Period Focus Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Document Fiscal Year Focus Document Fiscal Year Focus EX-101.PRE 5 seer-20220228_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover Page
Feb. 28, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Feb. 28, 2022
Entity Registrant Name Seer, Inc.
Entity File Number 001-39747
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-1153150
Entity Address, Address Line One 3800 Bridge Parkway
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 453-0000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, par value $0.00001 per share
Trading Symbol SEER
Entity Emerging Growth Company false
Entity Central Index Key 0001726445
Document Fiscal Year Focus
Document Fiscal Period Focus
Amendment Flag false
XML 7 seer-20220228_htm.xml IDEA: XBRL DOCUMENT 0001726445 2022-02-28 2022-02-28 false 0001726445 8-K 2022-02-28 Seer, Inc. DE 001-39747 82-1153150 3800 Bridge Parkway Suite 102 Redwood City CA 94065 650 453-0000 false false false false Class A Common Stock, par value $0.00001 per share SEER false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://seer.bio/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports seer-20220228.htm a8k-12312021exhibit.htm seer-20220228.xsd seer-20220228_lab.xml seer-20220228_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "seer-20220228.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "seer-20220228.htm" ] }, "labelLink": { "local": [ "seer-20220228_lab.xml" ] }, "presentationLink": { "local": [ "seer-20220228_pre.xml" ] }, "schema": { "local": [ "seer-20220228.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "seer", "nsuri": "http://seer.bio/20220228", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "seer-20220228.htm", "contextRef": "i1416301bfbe947b8b3203e9bb52e89be_D20220228-20220228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://seer.bio/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "seer-20220228.htm", "contextRef": "i1416301bfbe947b8b3203e9bb52e89be_D20220228-20220228", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://seer.bio/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001628280-22-004232-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-22-004232-xbrl.zip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end